Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Terminated Phase 3 Interventional

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

NCT00130260
View directory record Official record
Conditions
Staphylococcal Infections, Chronic Kidney Failure
Interventions
Staph aureus types 5 and 8 conjugate vaccine, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

NCT06727058
View directory record Official record
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
View directory record Official record
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
17
States / cities
Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

NCT01335191
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (1.0 mg), Placebo
Biological · Other
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

NCT00214461
View directory record Official record
Conditions
Clostridium Infections
Interventions
Vaccine diluent buffer (Placebo), C. difficile toxoid vaccine (2 µg), C. difficile toxoid vaccine (10 µg), C. difficile toxoid vaccine (50 µg)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Orlando, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

4 Pillars Toolkit for Adolescent Vaccination

NCT02165722
View directory record Official record
Conditions
Adolescent HPV Vaccine, Adolescent Influenza Vaccine
Interventions
4 Pillars Toolkit
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Messaging for Vaccination

NCT05182554
View directory record Official record
Conditions
Vaccination Refusal, COVID-19 Pandemic
Interventions
Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845
View directory record Official record
Conditions
Healthy
Interventions
rLP2086, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 25 Years
Enrollment
3,301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine
Biological
Lead sponsor
University of Maryland Greenebaum Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

NCT00427895
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005947
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T, Placebo
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
34
States / cities
Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 3 Interventional

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

NCT00005758
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 17, 2026, 5:01 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

NCT04498247
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V591, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hollywood, Florida • Wichita, Kansas • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 (vanutide cridificar)
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 17, 2026, 5:01 PM EDT
Recruiting Phase 1 Interventional

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314
View directory record Official record
Conditions
Influenza, Human+COVID-19
Interventions
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 17, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero, Saline Placebo, Havrix, MenABCWY
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 18 Years
Enrollment
1,063 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 17, 2026, 5:01 PM EDT